Curated dataset · n=61 verified deals · Not live market data · Scores are descriptive, not forecasts.
You are here

Deals — Network graph, deal flow, valuation matrix, and acquirer landscape.

Nine Continents Medical
→
Coloplast

Acquisition · Cash · COLO-B · announced Nov 3, 2020

View in network
  1. Announced

    Nov 3, 2020

  2. Closed

    Nov 3, 2020

Economics

Cash()

Pre-deal · pre-deal mark: 2020, year precision · rounding grid ±$100M · Coloplast press release — Nine Continents Medical acquisition, 2020

$145M upfront + contingent milestone payment

Target

Nine Continents Medical

Pelvic Health · Clinical / therapeutic

HQ Dayton, OH · Founded 2014

Implantable tibial nerve stimulator (ITNS) for overactive bladder — miniaturized, self-powered device placed under local anesthesia; no patient activation or recharging required

  • Globe Newswire — Coloplast press release (Nov 3, 2020)

Acquirer

Coloplast (COLO-B)

Pelvic Health

HQ Humlebæk, Denmark

Why this buyer

Curated copy from the verified dataset — not an 8-K LLM summary

Implantable tibial nerve stimulator enters Coloplast into OAB 3rd-line therapy market — 80M+ people globally with OAB symptoms, ~3M candidates for device therapy

Evidence ladder

Single-sourceValue disclosed
  1. Secondary (press / IR)

    Globe Newswire — Coloplast press release (Nov 3, 2020)

Limitations

  • Single-source or weak corroboration — treat valuation and timing as directional.
  • $145M upfront + contingent milestone payment
  • Pre-deal valuation sourced from: Coloplast press release — Nine Continents Medical acquisition, 2020. Pre-deal market-cap and funding citations do not corroborate the acquisition.

Valuation peers · Pelvic Health

Same sector, same deal type, announced within ±3 years, disclosed value within 0.25×–4× of this transaction. Ranked by evidence class, then same acquirer, until you sort.

Why included
Cogentix MedicalLaborie Medical TechnologiesMar 12, 2018same evidence class

Other verified deals by Coloplast

Acquirer program history not already listed as a valuation peer or adjacency row.

No further verified deals

Other verified transactions by Coloplast are already listed above, or none are in the dataset.

Patient empowerment context

Patient empowerment baseline (HLTH 2022)

No curated mapping — Nine Continents Medical (Pelvic Health). HLTH/Outcomes4Me 2022 baseline is Breast cancer care continuum (HLTH 2022). No curated mapping for this target in the verified crosswalk.

Research workspace (includes heuristic crosswalk) →

Related verified workspaces

Lacuna is a curated public-source sample, not a census of women's-health M&A. Coverage varies by sector, geography, disclosure availability, and women's-health scope. Undisclosed transaction values are excluded from disclosed-value totals.

Curated verified dataset v11 · updated 2026-10-19 · 1 citations on this deal · Data compiled from public sources for educational visualization. Verify independently before any commercial use.